secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeyondSpring Inc. (BYSI)
CIK:        0001677940
Form:       8-K
Filed at:   2026-09-29T11:03:38+00:00
Accession:  0001171843-26-006273
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

BeyondSpring wins FDA Fast Track for Plinabulin in post-ICI NSCLC; sells China unit to fund DUBLIN-4
--------------------------------------------------------------------------------

- FDA granted Fast Track designation to Plinabulin plus docetaxel for 2L/3L advanced non-squamous NSCLC without actionable genomic alterations, post-ICI and platinum chemo.
- DUBLIN-4 Phase 3: ~442 patients randomized 1:1, overall survival primary endpoint with PFS and ORR secondary; prespecified interim analysis at 221 PFS events.
- BeyondSpring will sell BeyondSpring Ltd, which indirectly holds its majority stake in Dalian Wanchunbulin (Bulin), to Biolin Investment for no cash; Biolin funds the China portion of DUBLIN-4.
- If Bulin misses Target Enrollment within 3 years after closing and the shortfall is 90% or more, Biolin must return 100% of the Equity Interests to BeyondSpring.
- ATM program with Citizens JMP Securities covers up to 9,200,000 ordinary shares; agent commission up to 3.0% of gross proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677940/000117184326006273/0001171843-26-006273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677940/000117184326006273/f8k_092826.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-006273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer